ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.503,67
-0,19%
S&P 500
5.315,51
0,14%
US Dollar vs BRL
5,1154
0,21%
Bitcoin
69.758,04
-2,37%
Brent Oil
82,705
-0,99%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Axsome Therapeutics Inc (AXSM)

  7. Axsome Therapeutics Inc (AXSM) Notícias

AXSM

Axsome Therapeutics (AXSM)

Axsome Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AXSM
DataHoraFonteTítuloCódigoCompanhia
08/05/202408:00GlobeNewswire Inc.Axsome Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202418:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AXSMAxsome Therapeutics Inc
06/05/202409:09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202408:00GlobeNewswire Inc.Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
01/05/202408:00GlobeNewswire Inc.Axsome Therapeutics Recognizes May as Mental Health Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
15/04/202408:00GlobeNewswire Inc.Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:AXSMAxsome Therapeutics Inc
10/04/202408:00GlobeNewswire Inc.Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6NASDAQ:AXSMAxsome Therapeutics Inc
01/04/202408:00GlobeNewswire Inc.Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating DisorderNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202408:00GlobeNewswire Inc.Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202407:30GlobeNewswire Inc.Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyNASDAQ:AXSMAxsome Therapeutics Inc
19/03/202408:00GlobeNewswire Inc.Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderNASDAQ:AXSMAxsome Therapeutics Inc
05/03/202409:00GlobeNewswire Inc.Axsome Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
29/02/202420:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
27/02/202409:00GlobeNewswire Inc.Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
23/02/202410:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AXSMAxsome Therapeutics Inc
20/02/202409:00GlobeNewswire Inc.Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
20/02/202407:37IH Market NewsMarket Cautiousness Ahead of Retail Giants’ Earnings; Oil Prices DipNASDAQ:AXSMAxsome Therapeutics Inc
14/02/202417:46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AXSMAxsome Therapeutics Inc
23/01/202409:00GlobeNewswire Inc.Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20NASDAQ:AXSMAxsome Therapeutics Inc
04/01/202409:00GlobeNewswire Inc.Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated MilestonesNASDAQ:AXSMAxsome Therapeutics Inc
11/12/202309:00GlobeNewswire Inc.Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual MeetingNASDAQ:AXSMAxsome Therapeutics Inc
07/12/202309:00GlobeNewswire Inc.Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders TodayNASDAQ:AXSMAxsome Therapeutics Inc
22/11/202309:00GlobeNewswire Inc.Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7NASDAQ:AXSMAxsome Therapeutics Inc
21/11/202309:00GlobeNewswire Inc.Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
06/11/202309:00GlobeNewswire Inc.Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
06/11/202308:54IH Market NewsMonday’s Wall Street Highlights: Berkshire Hathaway, Tesla, GM, Unilever, and moreNASDAQ:AXSMAxsome Therapeutics Inc
02/11/202308:00GlobeNewswire Inc.Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023NASDAQ:AXSMAxsome Therapeutics Inc
24/10/202308:00GlobeNewswire Inc.Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
11/10/202308:00GlobeNewswire Inc.Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of DirectorsNASDAQ:AXSMAxsome Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AXSM

Seu Histórico Recente

COIN
RAINNWUSD
RAIN Network
LSE
48JK
Fp Fin.9e% S
NASDAQ
PRIMU
ASX
DXN
DXN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados